SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.
NASH
SerpinB3
hepatocytes
innate immunity
macrophages
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
04
2022
accepted:
20
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease worldwide. In 20-30% of patients, NAFLD can progress into non-alcoholic steatohepatitis (NASH), eventually leading to fibrosis, cirrhosis and hepatocellular carcinoma development. SerpinB3 (SB3), a hypoxia-inducible factor-2α dependent cysteine protease inhibitor, is up-regulated in hepatocytes during progressive NAFLD and proposed to contribute to disease progression. In this study we investigated the pro-inflammatory role of SB3 by employing phorbol-myristate acetate-differentiated human THP-1 macrophages exposed
Identifiants
pubmed: 35874657
doi: 10.3389/fimmu.2022.910526
pmc: PMC9304805
doi:
Substances chimiques
Antigens, Neoplasm
0
Cytokines
0
Inflammation Mediators
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
Serpins
0
Trem2 protein, mouse
0
squamous cell carcinoma-related antigen
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
910526Informations de copyright
Copyright © 2022 Novo, Cappon, Villano, Quarta, Cannito, Bocca, Turato, Guido, Maggiora, Protopapa, Sutti, Provera, Ruvoletto, Biasiolo, Foglia, Albano, Pontisso and Parola.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Viral Hepat. 2008 Apr;15(4):246-9
pubmed: 18248333
Immunity. 2020 Jun 16;52(6):1057-1074.e7
pubmed: 32362324
Lab Invest. 2010 Jul;90(7):1016-23
pubmed: 20212457
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
JHEP Rep. 2019 Feb 23;1(1):30-43
pubmed: 32149275
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Oncotarget. 2015 Feb 10;6(4):2206-21
pubmed: 25544768
Hepatology. 2014 Mar;59(3):886-97
pubmed: 24115128
Hepatology. 2018 Jun;67(6):2196-2214
pubmed: 29266399
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817100
Cell Mol Immunol. 2021 Jan;18(1):45-56
pubmed: 33041338
Mol Cell. 2019 Aug 8;75(3):644-660.e5
pubmed: 31398325
Gut. 2020 Oct;69(10):1877-1884
pubmed: 32381514
PLoS One. 2012;7(7):e40658
pubmed: 22808225
Front Endocrinol (Lausanne). 2020 Apr 29;11:259
pubmed: 32411096
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
Semin Liver Dis. 2012 Feb;32(1):30-8
pubmed: 22418886
Mol Med. 2015 May 22;21:453-65
pubmed: 26018806
Int J Mol Med. 2010 Jan;25(1):137-43
pubmed: 19956912
Gastroenterology. 2021 Sep;161(3):1030-1042.e8
pubmed: 34416976
J Hepatol. 2019 Oct;71(4):823-833
pubmed: 31300231
J Allergy Clin Immunol. 2011 Jan;127(1):254-61, 261.e1-6
pubmed: 21126757
Cell Mol Gastroenterol Hepatol. 2022;13(2):459-482
pubmed: 34655812
Semin Cell Dev Biol. 2017 Feb;62:170-177
pubmed: 27637160
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
J Hepatol. 2018 Feb;68(2):326-334
pubmed: 29122695
Exp Biol Med (Maywood). 2012 Dec;237(12):1474-82
pubmed: 23354406
J Hepatol. 2015 Apr;62(1 Suppl):S15-24
pubmed: 25920084
J Hepatol. 2011 May;54(5):975-83
pubmed: 21145823
Mol Aspects Med. 2019 Feb;65:37-55
pubmed: 30213667
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Semin Liver Dis. 2017 Aug;37(3):189-197
pubmed: 28847030
Gastroenterology. 2020 May;158(7):1984-1998.e3
pubmed: 32061596
Hepatology. 2014 Apr;59(4):1393-405
pubmed: 24254368
Hepatology. 2012 Feb;55(2):622-33
pubmed: 22120903
Sci Rep. 2017 Jun 13;7(1):3420
pubmed: 28611447
Cell Metab. 2015 Dec 1;22(6):1078-89
pubmed: 26603189
Sci Rep. 2013 Oct 28;3:3056
pubmed: 24162160
J Hepatol. 2015 May;62(5):1148-55
pubmed: 25477264
PLoS One. 2013 Dec 18;8(12):e83481
pubmed: 24367597
Hepatology. 2016 Apr;63(4):1310-24
pubmed: 26699087
Immunity. 2020 Sep 15;53(3):641-657.e14
pubmed: 32888418
Cells. 2021 Jul 13;10(7):
pubmed: 34359934
Nat Rev Endocrinol. 2017 Sep;13(9):509-520
pubmed: 28621339
Cell. 2019 Jul 25;178(3):686-698.e14
pubmed: 31257031
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Hepatology. 2018 Apr;67(4):1270-1283
pubmed: 28940700
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
J Hepatol. 2021 Feb;74(2):442-457
pubmed: 33161047
Transl Gastroenterol Hepatol. 2021 Jan 05;6:5
pubmed: 33409399